Danaher Co. (NYSE:DHR) Shares Acquired by Malaga Cove Capital LLC

Malaga Cove Capital LLC increased its stake in shares of Danaher Co. (NYSE:DHR) by 15.8% during the 4th quarter, Holdings Channel.com reports. The fund owned 4,339 shares of the conglomerate’s stock after purchasing an additional 591 shares during the quarter. Malaga Cove Capital LLC’s holdings in Danaher were worth $1,004,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Wellington Management Group LLP increased its stake in Danaher by 18.6% in the third quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock valued at $6,185,203,000 after purchasing an additional 3,905,449 shares during the period. Allen Investment Management LLC increased its position in Danaher by 1,440.7% in the 3rd quarter. Allen Investment Management LLC now owns 1,100,399 shares of the conglomerate’s stock valued at $273,009,000 after acquiring an additional 1,028,976 shares during the period. J.P. Morgan Private Wealth Advisors LLC purchased a new stake in Danaher during the 3rd quarter valued at approximately $178,850,000. Alecta Tjanstepension Omsesidigt acquired a new stake in Danaher during the 4th quarter worth approximately $161,994,000. Finally, Harris Associates L P grew its stake in shares of Danaher by 27.7% in the 3rd quarter. Harris Associates L P now owns 2,963,899 shares of the conglomerate’s stock valued at $735,343,000 after purchasing an additional 642,759 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

DHR has been the subject of several recent research reports. Bank of America increased their price target on Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a report on Wednesday, April 24th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Royal Bank of Canada lifted their price objective on Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Raymond James raised their price target on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Finally, Barclays upped their price objective on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 24th. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and an average price target of $267.31.

Danaher Trading Up 0.6 %

Shares of NYSE:DHR traded up $1.54 during trading on Friday, reaching $248.38. The stock had a trading volume of 1,787,817 shares, compared to its average volume of 2,914,990. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $259.00. The business has a fifty day moving average price of $248.48 and a 200-day moving average price of $232.27. The stock has a market cap of $183.97 billion, a P/E ratio of 42.10, a PEG ratio of 3.82 and a beta of 0.83. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business’s revenue for the quarter was down 2.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.36 EPS. As a group, analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, April 26th. Shareholders of record on Thursday, March 28th were given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date of this dividend was Wednesday, March 27th. This is an increase from Danaher’s previous quarterly dividend of $0.24. Danaher’s payout ratio is 18.31%.

Insider Buying and Selling

In related news, Director Alan G. Spoon sold 708 shares of the firm’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the sale, the director now directly owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, Director Alan G. Spoon sold 708 shares of the stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the transaction, the director now owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joakim Weidemanis sold 22,433 shares of Danaher stock in a transaction that occurred on Thursday, April 25th. The stock was sold at an average price of $250.46, for a total value of $5,618,569.18. Following the sale, the executive vice president now owns 90,412 shares in the company, valued at $22,644,589.52. The disclosure for this sale can be found here. In the last quarter, insiders sold 107,273 shares of company stock valued at $26,813,819. 11.10% of the stock is currently owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.